RecruitingAsthma
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
Sponsor: AstraZeneca
You may qualify if…
- ✓ Age 18 to 75 years of age
- ✓ acceptable FEV1 (according to ATS and ERS)
- ✓ compliance with study procedures All Asthma Cohorts
- ✓ physician diagnosed Asthma greater or equal to 3 months prior to screening visit
You may not qualify if…
- ✕ history of alcohol or drug abuse within the past year
- ✕ pregnant at time of an assessment
- ✕ has an altered mental status at the time of informed consent
- ✕ receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
- ✕ history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
- ✕ terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
- ✕ Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.
Source: ClinicalTrials.gov · NCT06419413 · last updated 2026-08-18